KitoZyme has received the CE certification and marketing authorisation for the entire European market for two new medical devices to prevent and treat certain intestinal disorders
Through scientific partnerships with many foreign and Belgian universities, KitoZyme has perfected KiOtransine, a new prebiotic that contributes to the restoration of the microbiota equilibrium, without causing adverse reactions to the intestinal system.
“Because of our novel patented biopolymers of fungal origin, non-genetically modified, our company has positioned itself as an expert in intestinal microbiota,” said François Blondel, CEO of KitoZyme.
This prebiotic, unique in the world and already marketed for several months in the US, is now going to be introduced in the European Union.
“With this European marketing authorisation, we intend to develop commercial partnerships in France, Italy, Germany and Poland, for launches in pharmacies within the year,” he added.
Simultaneously, KitoZyme continues its scientific research and product development programmes, both for human health and animal nutrition.
The human digestive system is host to thousands of billions of bacteria and other micro-organisms, known collectively as the intestinal microbiota, which influence the health and well-being of each individual.
There is a broad scientific consensus that an unbalanced intestinal flora can cause serious disorders of the gastrointestinal system such as irritable bowel syndrome, Crohn's disease, as well as diabetes or obesity.